Vedroprevir
Alternative Names: GS-9451; VDVLatest Information Update: 05 Mar 2015
At a glance
- Originator Gilead Sciences
- Class Amides; Antivirals; Carbamates; Carboxylic acids; Cyclopentanes; Cyclopropanes; Hydroxyquinolines; Macrocyclic compounds; Morpholines; Pyrrolidines; Thiazoles
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 01 Feb 2015 Gilead Sciences completes a phase II trial for Hepatitis C (Combination therapy) in USA (NCT02226549)
- 07 Oct 2014 Gilead Sciences completes enrolment in a phase II trial in Hepatitis C (Combination therapy) in USA (NCT02226549)
- 01 Jul 2014 Phase-II clinical trials in Hepatitis C (Combination therapy, Treatment-experienced) in USA (PO)